Beta Bionics (NASDAQ:BBNX) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Beta Bionics from “sell” to “hold.” Overall analyst sentiment is more favorable, with a “Moderate Buy” consensus and an average price target of $21.90.
• The FDA cleared Beta Bionics’ Mint patch pump, with a U.S. launch planned for early 2027. The company also raised $172.5 million to fund commercialization, manufacturing, research and development, and working capital.
• Risks remain, including dilution from the equity offering, ongoing securities litigation allegations, insider share sales, and fiscal 2026 revenue guidance of $121 million–$126 million, below the roughly $133.9 million analyst consensus.

Beta Bionics (NASDAQ:BBNX - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

BBNX has been the topic of several other reports. Leerink Partners increased their target price on Beta Bionics from $24.00 to $27.00 and gave the stock an "outperform" rating in a research report on Monday. Weiss Ratings raised Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 18th. UBS Group restated a "buy" rating and set a $25.00 price target on shares of Beta Bionics in a research note on Tuesday. Truist Financial restated a "buy" rating and issued a $23.00 price objective (up from $22.00) on shares of Beta Bionics in a report on Tuesday. Finally, The Goldman Sachs Group lifted their price objective on Beta Bionics from $17.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $21.90.

Beta Bionics Stock Performance

Shares of BBNX stock opened at $21.89 on Friday. The firm has a market capitalization of $984.83 million, a price-to-earnings ratio of -13.27 and a beta of 3.37. Beta Bionics has a one year low of $8.80 and a one year high of $32.71. The company has a 50 day moving average price of $17.66 and a 200 day moving average price of $14.05.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The company had revenue of $32.01 million for the quarter. As a group, equities analysts forecast that Beta Bionics will post -2.06 EPS for the current fiscal year.

Insider Activity at Beta Bionics

In other Beta Bionics news, CFO Stephen Feider sold 6,675 shares of the firm's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $127,559.25. Following the completion of the transaction, the chief financial officer directly owned 159,378 shares of the company's stock, valued at $3,045,713.58. This trade represents a 4.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 30,779 shares of the firm's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $20.13, for a total transaction of $619,581.27. Following the transaction, the insider directly owned 56,479 shares of the company's stock, valued at approximately $1,136,922.27. This represents a 35.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 103,561 shares of company stock worth $1,962,504 in the last ninety days. 5.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Beta Bionics

Large investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd raised its position in shares of Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company's stock valued at $61,000 after acquiring an additional 1,818 shares in the last quarter. Legal & General Group Plc bought a new position in Beta Bionics during the 2nd quarter worth $62,000. The Manufacturers Life Insurance Company bought a new stake in Beta Bionics in the second quarter valued at $172,000. ProShare Advisors LLC acquired a new position in shares of Beta Bionics during the fourth quarter valued at $217,000. Finally, Ieq Capital LLC bought a new position in shares of Beta Bionics during the second quarter worth about $229,000.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Beta Bionics’ Mint patch pump, expanding its diabetes-device portfolio beyond the iLet Bionic Pancreas. A full U.S. launch is planned for the first quarter of 2027, potentially giving the company a second growth platform. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: Beta Bionics closed a public offering that generated $172.5 million in gross proceeds, including full exercise of the underwriters’ option. The capital should support Mint’s commercialization, manufacturing, research and development, and working capital needs. Beta Bionics Announces Closing of $172.5 Million Public Offering
• Positive Sentiment: Analyst sentiment remains broadly favorable. Recent price-target increases and a reported “Moderate Buy” consensus reflect optimism surrounding Mint and longer-term demand for automated insulin-delivery systems.
• Neutral Sentiment: Insiders Mark Hopman and Mike Mensinger sold shares under pre-arranged Rule 10b5-1 plans. The transactions totaled roughly $678,000 and do not necessarily indicate a change in management’s outlook, though they may affect sentiment. Beta Bionics Insider Trading
• Negative Sentiment: The equity offering issued millions of shares and pre-funded warrants at $17.25, creating dilution for existing shareholders and potentially limiting near-term upside.
• Negative Sentiment: Multiple law firms publicized a securities class action alleging inadequate disclosure of FDA Form 483 and warning-letter issues, including quality-management, patient-safety and customer-complaint concerns. The allegations remain unproven, but the litigation creates regulatory, reputational and financial uncertainty; the lead-plaintiff deadline is November 3, 2026. BBNX Securities Class Action Alert
• Negative Sentiment: Fiscal 2026 revenue guidance of $121 million to $126 million is below the approximately $133.9 million analyst consensus, signaling weaker near-term growth expectations.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.